Cerevel Therapeutics Appoints Paul Burgess as Main

Mr. Burgess will be accountable for main Cerevel’s business growth and excellent groups

Mr. Burgess to be a part of Cerevel powerful June 20, 2023

CAMBRIDGE, Mass., June 15, 2023 (Globe NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a organization focused to unraveling the mysteries of the brain to handle neuroscience disorders, nowadays introduced the appointment of Paul Burgess as main small business development and strategic functions officer, effective June 20, 2023.

“I am so delighted to welcome Paul to Cerevel as our main business progress and strategic functions officer, with his demonstrated monitor record of success in the biotech and pharmaceutical field,” reported Ron Renaud, president and main government officer of Cerevel Therapeutics. “Paul delivers more than 20 decades of company growth and operational encounter to the corporation, and his insights and skills will be indispensable as we look for to become the premier neuroscience company.”  

“I seem forward to signing up for Cerevel through this pivotal time and supporting the mission to transform the lives of persons residing with some of the most devastating neuroscience health conditions,” mentioned Mr. Burgess. “Cerevel’s patient-centered method holds good promise for delivering new therapy selections for schizophrenia, Parkinson’s ailment, and epilepsy.”

About Paul Burgess
Paul Burgess is a biotechnology govt with more than 20 several years of knowledge performing at the two start-up businesses and larger pharmaceutical corporations. Mr. Burgess’s most modern job was main operating officer and main legal officer of Translate Bio. At Translate Bio, he led business enterprise growth, lawful, software administration, quality, technological functions and associate collaborations. He joined Translate Bio in 2015 and remained until finally 2021, when the firm was offered to Sanofi for $3.2 billion.

Prior to Translate Bio, Mr. Burgess worked in a authorized role at a amount of providers together with Scholar Rock, Civitas Therapeutics, BIND Therapeutics and Completely transform Pharmaceuticals. Previously in his profession, he also worked in the lab at Genetics Institute.

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the mind to deal with neuroscience illnesses. The firm is tackling diseases by combining its deep know-how in neurocircuitry with a target on focused receptor subtype selectivity and a differentiated technique to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five medical-phase investigational therapies and several preclinical compounds with the possible to handle a range of neuroscience conditions, together with schizophrenia, Alzheimer’s illness psychosis, epilepsy, worry ailment, and Parkinson’s ailment. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its recent exploration and advancement programs even though exploring new modalities via interior exploration initiatives, exterior collaborations, or probable acquisitions. For additional details, take a look at www.cerevel.com.

Exclusive Notice Pertaining to Ahead-Searching Statements
This push release includes forward-seeking statements that are based on management’s beliefs and assumptions and on details at this time out there to administration. In some instances, you can recognize forward-searching statements by the pursuing words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the adverse of these phrases or other equivalent terminology, though not all ahead-looking statements comprise these words and phrases. These statements include dangers, uncertainties and other things that may cause true final results, amounts of exercise, efficiency or achievements to be materially distinctive from the information expressed or implied by these forward-wanting statements. Despite the fact that we believe that we have a fair basis for every single forward-on the lookout statement contained in this press release, we warning you that these statements are based mostly on a combination of points and variables at this time acknowledged by us and our projections of the potential, about which we simply cannot be specific. Ahead-wanting statements in this press release consist of, but are not restricted to, statements about: the likely attributes and added benefits of our product candidates and the format, timing and goals of our product or service improvement actions and clinical trials. We are unable to guarantee you that the ahead-on the lookout statements in this push launch will establish to be correct. Furthermore, if the ahead-on the lookout statements demonstrate to be inaccurate, the inaccuracy could be material. Precise overall performance and final results might differ materially from these projected or suggested in the ahead-searching statements owing to numerous hazards and uncertainties, such as, between other people: clinical trial final results may perhaps not be favorable uncertainties inherent in the solution development approach (such as with regard to the timing of benefits and whether such outcomes will be predictive of potential results) the effects of COVID-19, the post-COVID ecosystem and other factors on the timing, development and benefits of medical trials our skill to recruit and enroll ideal sufferers in our clinical trials whether and when, if at all, our solution candidates will obtain approval from the Food and drug administration or other regulatory authorities, and for which, if any, indications levels of competition from other biotechnology providers uncertainties regarding intellectual home security and other pitfalls discovered in our SEC filings, which includes those beneath the heading “Risk Factors” in our Quarterly Report on Kind 10-Q submitted with the SEC on May possibly 3, 2023 and our subsequent SEC filings. In light-weight of the major uncertainties in these forward-on the lookout statements, you need to not regard these statements as a representation or warranty by us or any other particular person that we will attain our aims and options in any specified time body, or at all. The forward-searching statements in this push release characterize our views as of the day of this press launch. We anticipate that subsequent occasions and developments will induce our sights to adjust. Nevertheless, even though we may elect to update these forward-seeking statements at some stage in the upcoming, we have no present intention of accomplishing so besides to the extent expected by relevant legislation. You really should, consequently, not rely on these forward-on the lookout statements as symbolizing our views as of any date subsequent to the date of this press release.

Media Call:
Anna Robinson
Cerevel Therapeutics
[email protected]

Trader Get in touch with:
Matthew Calistri
Cerevel Therapeutics
[email protected]